We thank Li and Wang for their thoughtful appraisal of our study and for emphasizing the growing need for phenotype-individualized approaches in IgG4-related disease (IgG4-RD) [1,2]. Their comments align with several considerations we also regard as central to the evolving therapeutic framework of this condition and that were already covered, at least in part, in our discussion.
